The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAlliance Pharma Share News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.40
Bid: 35.40
Ask: 35.65
Change: 0.40 (1.14%)
Spread: 0.25 (0.706%)
Open: 35.05
High: 35.60
Low: 35.00
Prev. Close: 35.00
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alternative Income assets fall; Aura wins conventions

Wed, 01st Feb 2023 21:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Alternative Income REIT PLC - London-based real estate investment company - Net asset value per share as at December 31 stands at 84.3 pence, down 13% compared to 97.0p as at September 30. Records a NAV total return of negative 11.6% versus 2.3% a quarter prior. Attributes this to a decrease in the portfolio valuation. Declares a second interim quarterly dividend of 1.375p per share for the quarter. Reconfirms its dividend target of at least 5.7pps. Rent collection remains resilient with 100% expected for the December 2022 quarter, it adds.

----------

Aura Energy Ltd - Australia-based minerals company with polymetallic and uranium projects in Europe and Africa - Signs mining conventions providing tenure security and fiscal certainty for an initial 30-year period with the government of Mauritania. Notes that this is a key milestone to support financing the development of the Tiris project. "What we see the is potential of the Tiris region in the uranium world. With the formalisation of our Mining Convention and our partnership with ANARPAM, we are keen to work with the government of Mauritania to develop the Tiris resource. Our increased knowledge and our belief in the quality of the resource gained from the drilling program and the expansion studies, to be released imminently, we believe will allow us to develop a world-class uranium operation," Chair Phil Mitchell comments.

----------

Maven Income & Growth VCT 5 PLC - London-based investment firm - Confirms that its unaudited net asset value as at November 30 amounted to 35.40 pence per share. Proposes a final dividend of 0.50 pence per share for the year that ended November 30.

----------

Maven Income & Growth VCT 3 PLC - London-based venture capital trust - Confirm that its unaudited net asset value per share as at November 30 stood at 57.32 pence per share. Proposes that a final dividend of 1.90p per share should be paid for the year ended November 30.

----------

Kodal Minerals PLC - mineral exploration and development company focused on lithium and gold assets in West Africa - Confirms the receipt of a USD7.0 million deposit agreed upon with Hainan Mining Co Ltd. This is part of a conditional funding package of USD117.8 million announced on January 19 that will provide full financing for the development and commencement of production at the Bougouni lithium project in Mali. Notes that the funding transaction remains subject to Chinese regulatory approvals, among other things.

----------

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Promotes non-executivce director Richard Jones to senior independent director from non-executive director. He held the position since 2019, the company says. "I am also pleased to appoint Richard Jones as our first senior independent director. Richard will help support and expand our stakeholder engagement programme, building on his extensive experience in capital markets and leveraging his strong networks with shareholders," Chair David Cook says.

----------

Mkango Resources Ltd - Vancouver-based mineral exploration and development company - Signs definitive agreements with CoTec Holdings Corp in relation to a GBP2 million convertible loan agreement in Mkango, a GBP1.5 million equity investment in Maginito, and a co-operation agreement regarding future investments in rare earth processing technology opportunities in the US, subject to closing.

----------

Valeura Energy Inc - Calgary, Canada-based upstream oil & gas company - Raises CAD10 million, or GBP6.1 million, in a private placement of 3.9 million shares at CAD2.54 each. Says that the net proceeds from will be used to fund the company's pre-production operations at the Wassana field and its Wassana infill drilling programme and for general corporate purposes. Expects the closing of the offering to occur on or about February 9.

----------

Vulcan Industries PLC - London-based engineering services firm - Records revenue of GBP968,000 in the nine months to year-end, changed from a year before. Pretax loss in the period narrows to GBP697,000 from GBP1.0 million a year before. Notes that it identified further potential additional acquisition opportunities and will make further announcements as this progress.

----------

Advanced Medical Solutions Group PLC - Cheshire, England-based developer and maker of tissue-healing technology - Buys Connexicon Medical Ltd for an up-front payment of EUR7 million with further deferred payments, dependent on the delivery of certain "research & development, regulatory and commercial milestones between 2023 and 2027." "The acquisition will unlock significant commercial, R&D, regulatory, marketing and operational synergies that we are confident will enhance the scope of both companies. We are excited to add more tissue sealant expertise, products and brands to the AMS franchise ensuring that we remain at the forefront of this expanding market," Chief Executive Chris Meredith comments.

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
12 Dec 2019 16:11

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
27 Nov 2019 15:00

Alliance Pharma handing back 'Xonvea' rights to Duchesnay

(Sharecast News) - Alliance Pharma has reached agreement with Duchesnay of Canada to return the UK and EU licensing rights to 'Xonvea', a prescription medicine for the treatment of nausea and vomiting of pregnancy where conservative management has failed, it announced on Wednesday.

Read more
27 Nov 2019 12:33

Alliance Pharma Exits Xonvea Licensing Deal Amid Slow Sales Uptake

Alliance Pharma Exits Xonvea Licensing Deal Amid Slow Sales Uptake

Read more
17 Sep 2019 16:12

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 18 September KingfisherHalf Year ResultsAccesso TechnologyHalf Year Year Year

Read more
10 Jul 2019 16:12

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 11 July Kenmare ResourcesHalf Year ProductionMcBrideTrading GroupFull

Read more
1 Jul 2019 15:35

Alliance Pharma Founder & Former Chief Executive John Dawson Departs

(Alliance News) - Alliance Pharma PLC said on Monday founder & former chief executive John Dawson decided to step down from the board.Dawson, who was a non-executive director at the on

Read more
16 May 2019 17:55

UK Shareholder Meetings Calendar - Next 7 Days

Friday 17 MayRestaurant GroupBank of Georgia GroupCentaur MediaCairn Continental 20

Read more
10 Apr 2019 16:05

Alliance Pharma's 'Xonvea' gets approval in Ireland

(Sharecast News) - Alliance Pharma announced on Wednesday that 'Xonvea' has gained marketing approval in the Republic of Ireland from the country's medicines regulator, the Health Products Regulatory Authority, for the treatment of nausea and vomiting of pregnancy where conservative management has failed.

Read more
10 Apr 2019 12:27

Alliance Pharma Gets Approval For Anti-Nausea Drug Xonvea In Ireland

LONDON (Alliance News) - Alliance Pharma PLC on Wednesday said its Xonvea drug has been approved in Ireland to treat nausea and vomiting of pregnancy.The Irish marketing approval is first

Read more
26 Mar 2019 11:33

Alliance Pharma Raises Annual Dividend Amid Strong Revenue Growth

LONDON (Alliance News) - Alliance Pharma on Tuesday raised its dividend for 2018 amid a strong revenue performance, though profit fell due to impairments.The pharmaceutical retailer said to

Read more
19 Mar 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 20 March KingfisherFull Year ResultsCentaur MediaFull Year GroupHalf

Read more
21 Jan 2019 12:42

Alliance Pharma's revenues climb as 'star' products shine

(Sharecast News) - Alliance Pharma on Monday reported a jump in revenue after a strong performance from its 'star' products and newly acquired Nizoral brand.

Read more
14 Jan 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 15 January Boohoo GroupTrading Statement Gym GroupTrading Workshop Year Year

Read more
2 Oct 2018 09:56

Alliance Pharma launches Xonvea in the UK

(Sharecast News) - Alliance Pharma launched its prescription product for the treatment of nausea and vomiting of pregnancy across the UK on Tuesday.

Read more
1 Oct 2018 13:02

Strategic Equity Capital Underperforms Against Benchmark In Year

LONDON (Alliance News) - Strategic Equity Capital PLC said on Monday it underperformed against its benchmark for its recently ended financial year, due to an undervalued portfolio.The said

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.